Skip to main content

Imaging

GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations

Jun 29, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
Yes No

Can we stop RA before it happens?

Jun 09, 2022

Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals. While it is often a point of substantive discussion at EULAR, this year’s meeting in Copenhagen provided further data on how therapy

Read Article
Gender

Time to consider gender stratification in AxSpA diagnosis and management

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked. Two abstracts have shed light on relevant gender-based differences in AxSpA assessment or treatment.

Read Article
ice cubes

Topical therapies take centre stage

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM
Jun 04, 2022
Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
EULAR,poster

EULAR 2022 – Day 3 Report

Jun 03, 2022

By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations

Read Article
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores. Synovial hypertrophy most responsive. Hands and feet, wrist and knees most affected and responsive. @RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 03, 2022
#EULAR2022 POS0276 Xray & US for CPPD: US: sensitivity in all sites Xray: highly specific, low sensitivity Combo: Best for patients with Negative Xray or Inconclusive US (only one positive site) @Rheumnow @MymaAlbaydaMD @USSONAR_Rh
Jun 03, 2022
Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI. Early changes in PsO may suggest a PsA-like MRI pattern may be present! Is this how we predict which PsO -> PsA? @RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 03, 2022
#EULAR2022 POS0278: Proof of concept US study: 💎CPP crystals do NOT generate posterior shadowing 💎MSU and hydroxyapatite did have shadowing, proportional to concentration of crystals @Rheumnow @MymaAlbaydaMD @USSONAR_Rh
Jun 03, 2022
There's nothing like a good physical examination Temporal artery exam & ultrasound vs temporal artery biopsy n=97 consecutive ?GCA pts from Carlo Salvarini's group Very decent PPV Those TA exam findings can be hard to find, but they're gold dust. POS0820 #EULAR2022 @RheumNow https://t.co/X9TzIqQBaB
Jun 03, 2022
What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 02, 2022
To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog@RheumNow https://t.co/0cTep6MHLu
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 02, 2022
Puzzle pieces

Polymyalgia rheumatica immunological puzzle further illustrated

Jun 02, 2022

Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015)

Read Article
Differentiating AS from OCI using CT scanning by Terrier et al showed that Subchondral Bone Attenuation Coefficient (SBAC) was higher in OCI than AS with a threshold of >7500 Hounslow Units discriminating the two conditions #EULAR2022 @RheumNow POS0126 https://t.co/8MdSe3Dqp7
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 02, 2022
#EULAR2022 Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394) 👁️Look for B-lines and pleural irregularity Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice @RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w
Jun 02, 2022
The PROOF study showed the predictors of radiographic progression included male gender HR 3.16, good response to NSAIDs HR 4.66, fulfillment of the imaging arm HR 6.64 and HLA-B27+ HR 3.99 by Poddubnyy et al #EULAR2022 @RheumNow OP0149

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 02, 2022
Dermatologists doing ultrasound (US) for earlier diagnosis of PsA? Grobelski et al showed in this study of 140 PsA patients, pre-US sensitivity/specifity was 81%/55%, post-US this changed to 62%/91%. Targeted US improved accuracy of referrals for PsA #EULAR2022 @RheumNow OP0029 https://t.co/iajqMuPqcd
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 01, 2022
RA.Ow02.jpg

A Big Leap in Modulating Rheumatoid Disease

Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. It is well known that seropositivity for rheumatoid factor and antibodies to cyclic citrullinated peptides (ACPA) can precede RA disease by many years.

Read Article
Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria ⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️ ⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️ ⭐️Ankylosis much higher in ♂️ (DOR 40!) @Rheumnow
Jun 01, 2022
↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx. Adjusted on smoking status, age and BMI. Shall we follow this group of patients more closely? OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 01, 2022
Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 painful joints. US ⬆️derm suspicion of PsA- but this is not feasible in busy offices and no reimbursement @RheumNow #EULAR2022 @eular_org OP0029 https://t.co/9a3gDgIBp0
Jun 01, 2022
#EULAR2022 TREAT-EARLIER OP0700 Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection ▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term ▶️Reduction in disease burden on MTX Rx @RheumNow https://t.co/SKlqMQQTui
Jun 01, 2022
×